The European Society of Cardiology kicks off its annual Congress
on Sunday. The theme of the Congress is “controversial issues in cardiology.”
The Hot Line & Clinical Trial Updates sessions address CV risk and
complications, drug treatment, interventional and device treatments, heart rate
and rhythm, and acute coronary syndromes. The trial we’ve been hearing the most
about is ARISTOTLE (Efficacy and Safety of Apixaban Compared to Warfarin for
Prevention of Stroke and Systemic Embolism in 18,202 Patients with Atrial
Fibrillation), but I’m sure there will be other big news along the way. CardioSource
Science & Quality Editor Chris Cannon, MD, FACC, has a video overview
of the ESC science on CVN.
I’m looking forward to the trip to Paris. The ACC has many
meetings planned with other cardiovascular societies, which we use to
strengthen our relationships and build global bridges. We can never forget that
cardiovascular disease isn’t just an American problem, or even a first world
country problem. As the U.N. has noted of late, cardiovascular risk factors and
disease are a huge problem in many developing nations as well. By building
relationships worldwide, the ACC is better enabling the spread of science and
education to improve patient care globally.
CardioSource is your source of coverage from ESC. Visit our meeting
coverage page for trial summaries, slide sets, video coverage and comments
from your colleagues. Follow @ACCinTouch
on Twitter to know exactly when these are live and get direct links. Video
coverage and photos will be available from our Facebook page as
well.
Going to ESC? Visit the ACC Booth (E200) to learn about the latest
international offerings, save 15% on education products purchased onsite
and register for ACC.12 in Chicago. On Sunday, there will be a members-only
meet-and-greet with ACC leadership (including me) at our stand. If interested,
please RSVP.